Biotech entity
All 2 tracked stories fall under one category: pharma. Arcturus Therapeutics is most often covered alongside Apogee Therapeutics, which appears in 1 of these 2 stories. That works out to roughly 0.8 stories per week across an 18-day span. At 5, the average consequence score sits below the same-window beat average of 6.1.
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. Arcturus Therapeutics is most often covered alongside Apogee Therapeutics, which appears in 1 of these 2 stories. That works out to roughly 0.8 stories per week across an 18-day span. At 5, the average consequence score sits below the same-window beat average of 6.1. Each story carries 2 original sources on average, compared with 3.5 for the broader beat in this window. We currently track 2 Biotech stories that mention Arcturus Therapeutics, published between March 2, 2026 and March 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 241 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Arcturus Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Apogee Therapeutics and Arcturus Therapeutics experienced a wave of conflicting analyst activity on Thursday, with both companies facing significant downgrades alongside new initiations. This institutional tug-of-war highlights the increasing volatility and selective nature of investment in mid-cap biotechnology firms.
Arcturus Therapeutics and Rigel Pharmaceuticals are set to report Q4 2025 results, highlighting a pivotal year for mRNA platform validation and oncology market expansion. Investors are focused on Arcturus's sa-mRNA commercial progress in Japan and Rigel's sales trajectory for its flagship hematology treatments.
Arcturus Therapeutics is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
